de Lastours Victoire, Maugy Elena, Mathy Vincent, Chau Françoise, Rossi Benjamin, Guérin François, Cattoir Vincent, Fantin Bruno
IAME, UMR-1137, Inserm and Université Paris Diderot, Paris, France.
Service de Médecine Interne, Hôpital Beaujon, APHP, Paris, France.
J Antimicrob Chemother. 2017 Jun 1;72(6):1574-1580. doi: 10.1093/jac/dkx043.
The ecological impact of ciprofloxacin on commensal enterococci is unknown.
Forty-eight healthy volunteers received ciprofloxacin from day (D) 0 to D14; stools were collected on D7, D14 and D42. Fluoroquinolone-susceptible and -resistant enterococci (FQ-SE and FQ-RE) were detected and quantified by culture, and identified by MALDI-TOF MS. The relative abundance of FQ-RE over FQ-SE was determined. The genetic basis of fluoroquinolone resistance was deciphered by partial sequencing of gyrA and parC genes. Clonal relatedness was determined by random amplification of polymorphic DNA PCR. Clinical trial no.: NCT00190151.
Enterococci were carried by 47/48 (98%) subjects. Total counts were reduced during ciprofloxacin therapy (4.0 and 3.9 log cfu/g on D7 and D14 versus 5.9 log cfu/g before and 6.9 log cfu/g after treatment; P < 0.05). Twenty-one out of 48 (44%) carried FQ-RE; among them, 21/21 carried Enterococcus faecium , 19 carried Enterococcus faecalis and 11 carried other species. Five out of 48 (10%) harboured FQ-RE (ciprofloxacin MIC >4 mg/L) before treatment (all E. faecium ), 6 on D7 (3 E. faecium and 3 E. faecalis ), 8 on D14 (4 E. faecium and 4 E. faecalis ) and 10 (21%) on D42 (9 E. faecium and 1 E. faecalis ). The relative abundance of FQ-RE increased from 44% on D0 to 73% and 75% on D7 and D14, respectively. No acquisition of fluoroquinolone resistance among endogenous D0 strains was evidenced. All (14/14) distinct Fluoroquinolone-resistant E. faecalis clones were gyrA / parC double mutants with high-level resistance (ciprofloxacin MIC >64 mg/L). In contrast, 34/35 E. faecium exhibited low-level resistance (ciprofloxacin MIC 4-32 mg/L) with no gyrA / parC mutation, but overexpressed the chromosomal Efm qnr gene. As compared with Fluoroquinolone-susceptible strains, Fluoroquinolone-resistant E. faecium were more frequently ampicillin resistant and Fluoroquinolone-resistant E. faecalis were more highly resistant to gentamicin.
Although intrinsically poorly susceptible to fluoroquinolones, gut populations of enterococci are highly impacted both quantitatively and qualitatively by ciprofloxacin.
环丙沙星对共生肠球菌的生态影响尚不清楚。
48名健康志愿者从第0天至第14天接受环丙沙星治疗;在第7天、第14天和第42天收集粪便。通过培养检测并定量氟喹诺酮敏感和耐药肠球菌(FQ-SE和FQ-RE),并通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)进行鉴定。确定FQ-RE相对于FQ-SE的相对丰度。通过对gyrA和parC基因进行部分测序来解读氟喹诺酮耐药的遗传基础。通过多态性DNA聚合酶链反应(PCR)随机扩增确定克隆相关性。临床试验编号:NCT00190151。
48名受试者中有47名(98%)携带肠球菌。环丙沙星治疗期间总菌数减少(第7天和第14天分别为4.0和3.9 log cfu/g,治疗前为5.9 log cfu/g,治疗后为6.9 log cfu/g;P<0.05)。48名受试者中有21名(44%)携带FQ-RE;其中,21/21携带粪肠球菌,19名携带屎肠球菌,11名携带其他菌种。48名受试者中有5名(10%)在治疗前携带FQ-RE(环丙沙星MIC>4 mg/L)(均为粪肠球菌),第7天有6名(3名粪肠球菌和3名屎肠球菌),第14天有8名(4名粪肠球菌和4名屎肠球菌),第42天有10名(21%)(9名粪肠球菌和1名屎肠球菌)。FQ-RE的相对丰度从第0天的44%分别增加到第7天和第14天的73%和75%。未证明内源性第0天菌株获得氟喹诺酮耐药性。所有(14/14)不同的耐氟喹诺酮屎肠球菌克隆均为gyrA/parC双突变体,具有高水平耐药性(环丙沙星MIC>64 mg/L)。相比之下,34/35株粪肠球菌表现出低水平耐药性(环丙沙星MIC 4 - 32 mg/L),无gyrA/parC突变,但染色体Efm qnr基因过度表达。与氟喹诺酮敏感菌株相比,耐氟喹诺酮粪肠球菌对氨苄西林耐药更为常见,耐氟喹诺酮屎肠球菌对庆大霉素耐药性更高。
尽管肠球菌对氟喹诺酮类药物本身敏感性较差,但环丙沙星在数量和质量上对肠道中的肠球菌群体均有高度影响。